FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991536770> ?p ?o ?g. }

• W1991536770 abstract "Although pharmacological and psychological interventions are both effective for major depression, in primary and secondary care settings antidepressant drugs remain the mainstay of treatment. Amongst antidepressants many different agents are available. Duloxetine hydrochloride is a dual reuptake inhibitor of serotonin and norepinephrine and has been licensed by the Food and Drug Administration in the US for major depressive disorder (MDD), generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain.To assess the evidence for the efficacy, acceptability and tolerability of duloxetine in comparison with all other antidepressant agents in the acute-phase treatment of major depression.MEDLINE (1966 to 2012), EMBASE (1974 to 2012), the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to March 2012. No language restriction was applied. Reference lists of relevant papers and previous systematic reviews were hand-searched. Pharmaceutical company marketing duloxetine and experts in this field were contacted for supplemental data.Randomised controlled trials allocating patients with major depression to duloxetine versus any other antidepressive agent.Two review authors independently extracted data and a double-entry procedure was employed. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability.A total of 16 randomised controlled trials (overall 5735 participants) were included in this systematic review. Of these, three trials were unpublished. We found 11 studies (overall 3304 participants) comparing duloxetine with one selective serotonin reuptake inhibitor (SSRI) (six studies versus paroxetine, three studies versus escitalopram and two versus fluoxetine), four studies (overall 1978 participants) comparing duloxetine with a newer antidepressants (three with venlafaxine and one with desvenlafaxine, respectively) and one study (overall 453 participants) comparing duloxetine with an antipsychotic drug which is also used as an antidepressive agent, quetiapine. No studies were found comparing duloxetine with tricyclic antidepressants. The pooled confidence intervals were rather wide and there were no statistically significant differences in efficacy when comparing duloxetine with other antidepressants. However, when compared with escitalopram or venlafaxine, there was a higher rate of drop out due to any cause in the patients randomised to duloxetine (odds ratio (OR) 1.62; 95% confidence interval (CI) 1.01 to 2.62 and OR 1.56; 95% CI 1.14 to 2.15, respectively). There was also some weak evidence suggesting that patients taking duloxetine experienced more adverse events than paroxetine (OR 1.24; 95% CI 0.99 to 1.55).Duloxetine did not seem to provide a significant advantage in efficacy over other antidepressive agents for the acute-phase treatment of major depression. No differences in terms of efficacy were found, even though duloxetine was worse than some SSRIs (most of all, escitalopram) and newer antidepressants (like venlafaxine) in terms of acceptability and tolerability. Unfortunately, we only found evidence comparing duloxetine with a handful of other active antidepressive agents and only a few trials per comparison were found (in some cases we retrieved just one trial). This limited the power of the review to detect moderate, but clinically meaningful differences between the drugs. As many statistical tests have been used in the review, the findings from this review are better thought of as hypothesis forming rather than hypothesis testing and it would be very comforting to see the conclusions replicated in future trials. Most of included studies were sponsored by the drug industry manufacturing duloxetine. As for all other new investigational compounds, the potential for overestimation of treatment effect due to sponsorship bias should be borne in mind. In the present review no trials reported economic outcomes. Given that several SSRIs and the great majority of antidepressants are now available as generic formulation (only escitalopram, desvenlafaxine and duloxetine are still on patent), more comprehensive economic estimates of antidepressant treatment effect should be considered to better inform healthcare policy." @default.
• W1991536770 created "2016-06-24" @default.
• W1991536770 creator A5007077090 @default.
• W1991536770 creator A5039199295 @default.
• W1991536770 creator A5040510734 @default.
• W1991536770 creator A5041725712 @default.
• W1991536770 creator A5052053764 @default.
• W1991536770 creator A5055378687 @default.
• W1991536770 creator A5080028737 @default.
• W1991536770 creator A5085050194 @default.
• W1991536770 date "2012-10-17" @default.
• W1991536770 modified "2023-09-30" @default.
• W1991536770 title "Duloxetine versus other anti-depressive agents for depression" @default.
• W1991536770 cites W114368807 @default.
• W1991536770 cites W1516838546 @default.
• W1991536770 cites W1550290244 @default.
• W1991536770 cites W1591259115 @default.
• W1991536770 cites W1770079579 @default.
• W1991536770 cites W1904816587 @default.
• W1991536770 cites W1964162160 @default.
• W1991536770 cites W1967378279 @default.
• W1991536770 cites W1979534890 @default.
• W1991536770 cites W1979892910 @default.
• W1991536770 cites W1983159214 @default.
• W1991536770 cites W1985237413 @default.
• W1991536770 cites W1985280182 @default.
• W1991536770 cites W1986578760 @default.
• W1991536770 cites W1987560991 @default.
• W1991536770 cites W1991137562 @default.
• W1991536770 cites W2000769256 @default.
• W1991536770 cites W2001307836 @default.
• W1991536770 cites W2003363634 @default.
• W1991536770 cites W2003952669 @default.
• W1991536770 cites W2010091722 @default.
• W1991536770 cites W2011606125 @default.
• W1991536770 cites W2013447731 @default.
• W1991536770 cites W2015712245 @default.
• W1991536770 cites W2018425549 @default.
• W1991536770 cites W2019015777 @default.
• W1991536770 cites W2022866457 @default.
• W1991536770 cites W2025918112 @default.
• W1991536770 cites W2032780198 @default.
• W1991536770 cites W2036379170 @default.
• W1991536770 cites W204046373 @default.
• W1991536770 cites W2047902057 @default.
• W1991536770 cites W2049111025 @default.
• W1991536770 cites W2049129528 @default.
• W1991536770 cites W2049165791 @default.
• W1991536770 cites W2051675429 @default.
• W1991536770 cites W2062251052 @default.
• W1991536770 cites W2062440421 @default.
• W1991536770 cites W2068959829 @default.
• W1991536770 cites W2069090735 @default.
• W1991536770 cites W2072303299 @default.
• W1991536770 cites W2073009660 @default.
• W1991536770 cites W2075245372 @default.
• W1991536770 cites W2076894270 @default.
• W1991536770 cites W2077771812 @default.
• W1991536770 cites W2084612570 @default.
• W1991536770 cites W2098354008 @default.
• W1991536770 cites W2100278846 @default.
• W1991536770 cites W2104981347 @default.
• W1991536770 cites W2111112809 @default.
• W1991536770 cites W2114613490 @default.
• W1991536770 cites W2116153150 @default.
• W1991536770 cites W2121017483 @default.
• W1991536770 cites W2125435699 @default.
• W1991536770 cites W2130235475 @default.
• W1991536770 cites W2131823335 @default.
• W1991536770 cites W2132577167 @default.
• W1991536770 cites W2136284733 @default.
• W1991536770 cites W2138309554 @default.
• W1991536770 cites W2140368769 @default.
• W1991536770 cites W2140505555 @default.
• W1991536770 cites W2142947341 @default.
• W1991536770 cites W2144981148 @default.
• W1991536770 cites W2149154629 @default.
• W1991536770 cites W2150287316 @default.
• W1991536770 cites W2153037374 @default.
• W1991536770 cites W2160795579 @default.
• W1991536770 cites W2165044084 @default.
• W1991536770 cites W2167251944 @default.
• W1991536770 cites W2169083980 @default.
• W1991536770 cites W2169698098 @default.
• W1991536770 cites W2276176430 @default.
• W1991536770 cites W2320184260 @default.
• W1991536770 cites W2405347857 @default.
• W1991536770 cites W4210997607 @default.
• W1991536770 cites W4214559180 @default.
• W1991536770 cites W4229883581 @default.
• W1991536770 cites W4234987987 @default.
• W1991536770 cites W4292806894 @default.
• W1991536770 cites W4361867719 @default.
• W1991536770 cites W51209413 @default.
• W1991536770 cites W70314342 @default.
• W1991536770 doi "https://doi.org/10.1002/14651858.cd006533.pub2" @default.
• W1991536770 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4171125" @default.
• W1991536770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23076926" @default.
• W1991536770 hasPublicationYear "2012" @default.
• W1991536770 type Work @default.

• next